

# **Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/NF181F8CB864EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: NF181F8CB864EN

## **Abstracts**

The 7 major necrotizing enterocolitis markets reached a value of US\$ 3.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 5.5 Billion by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The necrotizing enterocolitis market has been comprehensively analyzed in IMARC's new report titled "Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Necrotizing enterocolitis refers to a serious medical condition that primarily affects premature infants, especially those born before 32 weeks of gestation. It is characterized by inflammation and tissue death in the intestine, particularly in the colon and small intestine. The indications associated with this condition can vary in severity but often include feeding intolerance, abdominal distension, blood in the stool, lethargy, etc. In some cases, infants suffering from the ailment may exhibit signs of sepsis, such as a high temperature or an unstable heart rate. The diagnosis of necrotizing enterocolitis mainly involves a combination of clinical evaluation, laboratory tests, and imaging studies. The healthcare provider may also utilize abdominal scans to identify signs of intestinal damage or pneumatosis, which is the presence of gas in the intestinal wall. Additionally, blood tests might be conducted to aid in assessing the patient's overall health and detecting indications of infection or organ dysfunction.

The increasing cases of premature births, which make infants prone to inflammation and infection due to immature gastrointestinal systems, are primarily driving the necrotizing enterocolitis market. In addition to this, the inflating utilization of effective treatments, such as antibiotics and intravenous fluids, to manage the ailment and prevent further complications is creating a positive outlook for the market. These

therapies help to combat infections as well as maintain hydration and electrolyte balance in patients. Moreover, the widespread adoption of specialized feeding strategies, including parenteral nutrition and the slow advancement of enteral feeds, which can reduce the risk of disease development, is further bolstering the market growth. Apart from this, the rising usage of advanced medical technologies, such as imaging techniques like X-rays and ultrasound, since they aid in the accurate diagnosis of necrotizing enterocolitis cases, is acting as another significant growth-inducing factor. Additionally, the escalating implementation of preventive measures, including strict hygiene protocols and careful monitoring of high-risk neonates in neonatal intensive care units to curb the incidence of illness, is also augmenting the market growth. Furthermore, the rising R&D activities in the fields of regenerative drugs and stem cell therapies, which offer promising potential for improved treatment outcomes, are expected to drive the necrotizing enterocolitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the necrotizing enterocolitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for necrotizing enterocolitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the necrotizing enterocolitis market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the necrotizing enterocolitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the necrotizing enterocolitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current necrotizing enterocolitis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the necrotizing enterocolitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the necrotizing enterocolitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the necrotizing enterocolitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of necrotizing enterocolitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with necrotizing enterocolitis across the seven major markets?

What is the size of the necrotizing enterocolitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of necrotizing enterocolitis?

What will be the growth rate of patients across the seven major markets?

### Necrotizing Enterocolitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for necrotizing enterocolitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the necrotizing enterocolitis market?

What are the key regulatory events related to the necrotizing enterocolitis market?

What is the structure of clinical trial landscape by status related to the necrotizing enterocolitis market?

What is the structure of clinical trial landscape by phase related to the necrotizing enterocolitis market?

What is the structure of clinical trial landscape by route of administration related to the necrotizing enterocolitis market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 NECROTIZING ENTEROCOLITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 NECROTIZING ENTEROCOLITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 NECROTIZING ENTEROCOLITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 NECROTIZING ENTEROCOLITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 NECROTIZING ENTEROCOLITIS - UNMET NEEDS**

## **10 NECROTIZING ENTEROCOLITIS - KEY ENDPOINTS OF TREATMENT**

## **11 NECROTIZING ENTEROCOLITIS - MARKETED PRODUCTS**

- 11.1 List of Necrotizing Enterocolitis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 NECROTIZING ENTEROCOLITIS - PIPELINE DRUGS**

### 12.1 List of Necrotizing Enterocolitis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 IBP-9414 - Infant Bacterial Therapeutics

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 STP206 - Leadiant Biosciences

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13 NECROTIZING ENTEROCOLITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14 NECROTIZING ENTEROCOLITIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 NECROTIZING ENTEROCOLITIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Necrotizing Enterocolitis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Necrotizing Enterocolitis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

- 15.3.1 Necrotizing Enterocolitis - Market Size
  - 15.3.1.1 Market Size (2018-2023)
  - 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Necrotizing Enterocolitis - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Necrotizing Enterocolitis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Necrotizing Enterocolitis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Necrotizing Enterocolitis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Necrotizing Enterocolitis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Necrotizing Enterocolitis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Necrotizing Enterocolitis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Necrotizing Enterocolitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Necrotizing Enterocolitis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Necrotizing Enterocolitis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Necrotizing Enterocolitis - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Necrotizing Enterocolitis - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Necrotizing Enterocolitis - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

### 15.8.3 Necrotizing Enterocolitis - Access and Reimbursement Overview

## 15.9 Market Scenario - Japan

### 15.9.1 Necrotizing Enterocolitis - Market Size

#### 15.9.1.1 Market Size (2018-2023)

#### 15.9.1.2 Market Forecast (2024-2034)

### 15.9.2 Necrotizing Enterocolitis - Market Size by Therapies

#### 15.9.2.1 Market Size by Therapies (2018-2023)

#### 15.9.2.2 Market Forecast by Therapies (2024-2034)

### 15.9.3 Necrotizing Enterocolitis - Access and Reimbursement Overview

## **16 NECROTIZING ENTEROCOLITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 NECROTIZING ENTEROCOLITIS MARKET - SWOT ANALYSIS**

### 17.1 Strengths

### 17.2 Weaknesses

### 17.3 Opportunities

### 17.4 Threats

## **18 NECROTIZING ENTEROCOLITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Necrotizing Enterocolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/NF181F8CB864EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NF181F8CB864EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

